Phase II, Open Label, Non-randomized, Trial of BKM120 for Metastatic or Locally Advanced Cervical Cancer
Status:
Withdrawn
Trial end date:
2017-09-01
Target enrollment:
Participant gender:
Summary
This is a single arm open label phase II trial to evaluate the oral daily use of BKM 120 in
patients with recurrent unresectable or metastatic cervical cancer after palliative cisplatin
based regimen failure.
A complete treatment cycle is defined as a 28 days period.